Loading clinical trials...
Loading clinical trials...
A Single Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 When PF614 Solution is Co-Administered with Nafamostat, As an Immediate Release Solution And/or Extended Release (ER) Capsule Formulations in Healthy Subjects
Conditions
Interventions
PF614 solution
Naltrexone Hydrochloride
+1 more
Locations
1
United States
Quotient Sciences
Miami, Florida, United States
Start Date
December 1, 2021
Primary Completion Date
April 26, 2023
Completion Date
April 26, 2023
Last Updated
September 24, 2024
NCT07052162
NCT04961593
NCT06426836
NCT02456974
NCT06993636
NCT03717623
Lead Sponsor
Ensysce Biosciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions